Abstract

Background: There have been more clinical studies on the intervention of mifepristone combined with Guzhi Fufuing (GZFL) capsules in uterine fibroids (UF). However, there is a lack of strong evidence on the ability of combination therapy to reduce the size of leiomyosarcoma in non-surgical patients, and there is no recommended dose. Purpose: Evaluation of the effect of mifepristone combined with GZFL Capsule in patients with non-surgical uterine fibroids by means of meta-analysis, and discussion of the optimal dose. Methods: The experimental group used mifepristone plus GZFL capsules to intervene, and the control group used mifepristone to search the literature published as of October 4, 2022 for the treatment of uterine fibroids. Results: After screening, 20 articles comprising 2252 patients were selected from a total of 762 articles that were relevant. The test group’s overall effective rate was 94.49%, which was higher than the control group and 2.43% higher than the effective rate of the previous study (P<0.05). The group receiving medium doses had the highest OR value. In comparison to earlier research, the trial group not only beat the control group in terms of shrinking fibroids in size(P<0.05), but also had therapeutic benefits in controlling serum hormone levels in patients with uterine fibroids smaller than 5.5 cm (P<0.05), and also had fewer adverse events (P<0.05). Conclusion: For patients who don’t need surgery, mifepristone combined with GZFL capsule can shrink fibroids. 12.5 mg/d of mifepristone is advised as the ideal dose for combining both medications.